Novo Nordisk

Trend Analysis of Novo Nordisk

Momentum remains positive, but is still in a normalization phase after a period of strong share-price pressure over the past year and on a longer-term basis. Recent announcements around Wegovy mainly appear to confirm the strategic appeal of the anti-obesity ecosystem without materially changing Novo Nordisk’s fundamental profile in the short term; the main issue therefore remains the group’s ability to convert its